Market research
NERV Minerva Neurosciences Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 231M
- P/E ratio
- Not available
- Analyst target
- 10.3333
- Dividend yield
- Not available
- Beta
- -0.11
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US6033802058
- Market cap
- 231M
- P/E ratio
- Not available
- Analyst target
- 10.3333
- Dividend yield
- Not available
- Beta
- -0.11
About
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NERV discussion.
5 years, 4 months ago
Minerva Neurosciences, Inc is currently in a long term downtrend where the price is trading 24.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Minerva Neurosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 75.5% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.5% to $-7M since the same quarter in the previous year.
Based on the above factors, Minerva Neurosciences, Inc gets an overall score of 3/5.